492 related articles for article (PubMed ID: 15940147)
1. Pimecrolimus leads to an apoptosis-induced depletion of T cells but not Langerhans cells in patients with atopic dermatitis.
Hoetzenecker W; Ecker R; Kopp T; Stuetz A; Stingl G; Elbe-Bürger A
J Allergy Clin Immunol; 2005 Jun; 115(6):1276-83. PubMed ID: 15940147
[TBL] [Abstract][Full Text] [Related]
2. Tacrolimus ointment causes inflammatory dendritic epidermal cell depletion but no Langerhans cell apoptosis in patients with atopic dermatitis.
Schuller E; Oppel T; Bornhövd E; Wetzel S; Wollenberg A
J Allergy Clin Immunol; 2004 Jul; 114(1):137-43. PubMed ID: 15241357
[TBL] [Abstract][Full Text] [Related]
3. A randomized study of the safety, absorption and efficacy of pimecrolimus cream 1% applied twice or four times daily in patients with atopic dermatitis.
Ling M; Gottlieb A; Pariser D; Caro I; Stewart D; Scott G; Abrams K
J Dermatolog Treat; 2005 Aug; 16(3):142-8. PubMed ID: 16096179
[TBL] [Abstract][Full Text] [Related]
4. A randomized controlled trial of pimecrolimus cream 1% in adolescents and adults with head and neck atopic dermatitis and intolerant of, or dependent on, topical corticosteroids.
Murrell DF; Calvieri S; Ortonne JP; Ho VC; Weise-Riccardi S; Barbier N; Paul CF
Br J Dermatol; 2007 Nov; 157(5):954-9. PubMed ID: 17935515
[TBL] [Abstract][Full Text] [Related]
5. Pimecrolimus cream 1% in the long-term management of adult atopic dermatitis: prevention of flare progression. A randomized controlled trial.
Gollnick H; Kaufmann R; Stough D; Heikkila H; Andriano K; Grinienko A; Jimenez P;
Br J Dermatol; 2008 May; 158(5):1083-93. PubMed ID: 18341665
[TBL] [Abstract][Full Text] [Related]
6. Inflammatory cell numbers and cytokine expression in atopic dermatitis after topical pimecrolimus treatment.
Simon D; Vassina E; Yousefi S; Braathen LR; Simon HU
Allergy; 2005 Jul; 60(7):944-51. PubMed ID: 15932386
[TBL] [Abstract][Full Text] [Related]
7. Twice-daily versus once-daily applications of pimecrolimus cream 1% for the prevention of disease relapse in pediatric patients with atopic dermatitis.
Ruer-Mulard M; Aberer W; Gunstone A; Kekki OM; López Estebaranz JL; Vertruyen A; Guettner A; Hultsch T
Pediatr Dermatol; 2009; 26(5):551-8. PubMed ID: 19840309
[TBL] [Abstract][Full Text] [Related]
8. Results of a randomized, double-blind, vehicle-controlled efficacy trial of pimecrolimus cream 1% for the treatment of moderate to severe facial seborrheic dermatitis.
Warshaw EM; Wohlhuter RJ; Liu A; Zeller SA; Wenner RA; Bowers S; Schultz JC; Katz HI; McCormick CL; Parneix-Spake A
J Am Acad Dermatol; 2007 Aug; 57(2):257-64. PubMed ID: 17188780
[TBL] [Abstract][Full Text] [Related]
9. Long-term management of facial atopic eczema with pimecrolimus cream 1% in paediatric patients with mild to moderate disease.
Zuberbier T; Bräutigam M
J Eur Acad Dermatol Venereol; 2008 Jun; 22(6):718-21. PubMed ID: 18312323
[TBL] [Abstract][Full Text] [Related]
10. Review of pimecrolimus cream 1% for the treatment of mild to moderate atopic dermatitis.
Hebert AA
Clin Ther; 2006 Dec; 28(12):1972-82. PubMed ID: 17296454
[TBL] [Abstract][Full Text] [Related]
11. Skin physiological parameters confirm the therapeutic efficacy of pimecrolimus cream 1% in patients with mild-to-moderate atopic dermatitis.
Aschoff R; Schwanebeck U; Bräutigam M; Meurer M
Exp Dermatol; 2009 Jan; 18(1):24-9. PubMed ID: 18637133
[TBL] [Abstract][Full Text] [Related]
12. Gene expression is differently affected by pimecrolimus and betamethasone in lesional skin of atopic dermatitis.
Jensen JM; Scherer A; Wanke C; Bräutigam M; Bongiovanni S; Letzkus M; Staedtler F; Kehren J; Zuehlsdorf M; Schwarz T; Weichenthal M; Fölster-Holst R; Proksch E
Allergy; 2012 Mar; 67(3):413-23. PubMed ID: 22142306
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of nonsteroid pimecrolimus cream 1% in the treatment of atopic dermatitis in infants.
Ho VC; Gupta A; Kaufmann R; Todd G; Vanaclocha F; Takaoka R; Fölster-Holst R; Potter P; Marshall K; Thurston M; Bush C; Cherill R
J Pediatr; 2003 Feb; 142(2):155-62. PubMed ID: 12584537
[TBL] [Abstract][Full Text] [Related]
14. Pimecrolimus -- an anti-inflammatory drug targeting the skin.
Grassberger M; Steinhoff M; Schneider D; Luger TA
Exp Dermatol; 2004 Dec; 13(12):721-30. PubMed ID: 15560755
[TBL] [Abstract][Full Text] [Related]
15. A bilateral comparison study of pimecrolimus cream 1% and a topical medical device cream in the treatment of patients with atopic dermatitis.
Emer JJ; Frankel A; Sohn A; Lebwohl M
J Drugs Dermatol; 2011 Jul; 10(7):735-43. PubMed ID: 21720655
[TBL] [Abstract][Full Text] [Related]
16. Pimecrolimus cream 1%: a new development in nonsteroid topical treatment of inflammatory skin diseases.
Hebert AA; Warken KA; Cherill R
Semin Cutan Med Surg; 2001 Dec; 20(4):260-7. PubMed ID: 11770913
[TBL] [Abstract][Full Text] [Related]
17. Onset of pruritus relief with pimecrolimus cream 1% in adult patients with atopic dermatitis: a randomized trial.
Kaufmann R; Bieber T; Helgesen AL; Andersen BL; Luger T; Poulin Y; Al-Hafidh J; Paul C;
Allergy; 2006 Mar; 61(3):375-81. PubMed ID: 16436149
[TBL] [Abstract][Full Text] [Related]
18. Effect of pimecrolimus cream 1% on the long-term course of pediatric atopic dermatitis.
Papp K; Staab D; Harper J; Potter P; Puig L; Ortonne JP; Molloy S; Barbier N; Paul C;
Int J Dermatol; 2004 Dec; 43(12):978-83. PubMed ID: 15569038
[TBL] [Abstract][Full Text] [Related]
19. Effects of pimecrolimus cream 1% in the treatment of patients with atopic dermatitis who demonstrate a clinical insensitivity to topical corticosteroids: a randomized, multicentre vehicle-controlled trial.
Leung DY; Hanifin JM; Pariser DM; Barber KA; Langley RG; Schlievert PM; Abrams B; Hultsch T
Br J Dermatol; 2009 Aug; 161(2):435-43. PubMed ID: 19416245
[TBL] [Abstract][Full Text] [Related]
20. Pimecrolimus: new preparation. Me-too: too many risks, not beneficial enough in atopic dermatitis.
Prescrire Int; 2004 Dec; 13(74):209-12. PubMed ID: 15599989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]